Kalypsys

About Kalypsys

Kalypsys, Inc. was a pharmaceutical company established in 2001 as a spin-off from the Genomics Institute of the Novartis Research Foundation (GNF). The founding team included Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz, and Robert Downs. The San Diego-based company focused on accelerating the discovery and development of small molecule drugs, primarily targeting pain/inflammation, cardiovascular/metabolic diseases, and oncology.

Kalypsys operated by integrating high-throughput screening with high-throughput biology to more efficiently identify and advance promising compounds to clinical trials. The company's core technology, developed at GNF and commercialized by Kalypsys, was a robotic platform for quantitative high-throughput screening (qHTS). This system enabled the testing of vast compound libraries at multiple concentrations to generate comprehensive data for drug assays. Kalypsys utilized this platform for its internal drug pipeline and also partnered with major pharmaceutical companies, such as Merck & Co., to provide access to its advanced screening capabilities. This business model provided dual revenue streams: advancing its own therapeutic candidates and offering its technology platform as a service.

One of the company's founders, Kevin Lustig, later drew on his experience at Kalypsys, noting the bottlenecks in the research process, to co-found Scientist.com, a B2B marketplace for the pharmaceutical industry. Throughout its operation, Kalypsys achieved significant financial milestones, including a Series C financing round in November 2006 that raised $100 million, bringing its total private equity funding to $172 million since its inception in 2002. This funding was intended to advance its clinical pipeline, which included candidates for metabolic disorders (KD3010), neuropathic pain (KD7040), and tumors (KD5170). Despite its promising technology and pipeline, information about the company ceases after the late 2000s, with industry resources indicating it is no longer in operation.